Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial.

PubWeight™: 8.12‹?› | Rank: Top 0.1%

🔗 View Article (PMID 13678871)

Published in Lancet on September 06, 2003

Authors

Salim Yusuf1, Marc A Pfeffer, Karl Swedberg, Christopher B Granger, Peter Held, John J V McMurray, Eric L Michelson, Bertil Olofsson, Jan Ostergren, CHARM Investigators and Committees

Author Affiliations

1: McMaster Clinic, Room 252, Hamilton General Hospital, 237 Barton Street East, ON, L8L 2X2, Hamilton, Canada. yusufs@mcmaster.ca

Associated clinical trials:

Radiofrequency (RF) Ablation for Atrial Fibrillation (AF) in Patients With Heart Failure With Preserved Ejection Fraction (AF-HFpEF) | NCT04327596

Articles citing this

(truncated to the top 100)

Isosorbide Mononitrate in Heart Failure with Preserved Ejection Fraction. N Engl J Med (2015) 4.39

Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment. Eur Heart J (2010) 3.62

Effects of digoxin on morbidity and mortality in diastolic heart failure: the ancillary digitalis investigation group trial. Circulation (2006) 3.40

Association between guideline recommended drugs and death in older adults with multiple chronic conditions: population based cohort study. BMJ (2015) 3.34

Canadian Cardiovascular Society consensus conference recommendations on heart failure 2006: diagnosis and management. Can J Cardiol (2006) 3.20

Angiotensin receptor blockers and risk of myocardial infarction: meta-analyses and trial sequential analyses of 147 020 patients from randomised trials. BMJ (2011) 3.12

Angiotensin receptor blockers and risk of myocardial infarction: systematic review. BMJ (2005) 2.57

Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction. J Am Coll Cardiol (2012) 2.56

Longitudinal changes in ejection fraction in heart failure patients with preserved and reduced ejection fraction. Circ Heart Fail (2012) 2.53

Pre-clinical diastolic dysfunction. J Am Coll Cardiol (2013) 2.39

Epidemiology and clinical course of heart failure with preserved ejection fraction. Eur J Heart Fail (2010) 2.35

Exercise training in patients with heart failure and preserved ejection fraction: meta-analysis of randomized control trials. Circ Heart Fail (2014) 2.30

Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Ann Med (2010) 2.21

Clinical impacts of additive use of olmesartan in hypertensive patients with chronic heart failure: the supplemental benefit of an angiotensin receptor blocker in hypertensive patients with stable heart failure using olmesartan (SUPPORT) trial. Eur Heart J (2015) 2.11

Outcomes in ambulatory chronic systolic and diastolic heart failure: a propensity score analysis. Am Heart J (2006) 2.10

Effect of Selective Heart Rate Slowing in Heart Failure With Preserved Ejection Fraction. Circulation (2015) 2.02

Angiotensin receptor blockers and myocardial infarction. BMJ (2004) 2.02

Myocardial stiffness in patients with heart failure and a preserved ejection fraction: contributions of collagen and titin. Circulation (2015) 1.96

Exercise training in older patients with heart failure and preserved ejection fraction: a randomized, controlled, single-blind trial. Circ Heart Fail (2010) 1.93

Liver function abnormalities and outcome in patients with chronic heart failure: data from the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. Eur J Heart Fail (2009) 1.93

Diastolic and systolic heart failure are distinct phenotypes within the heart failure spectrum. Circulation (2011) 1.78

Canadian Cardiovascular Society Consensus Conference recommendations on heart failure update 2007: Prevention, management during intercurrent illness or acute decompensation, and use of biomarkers. Can J Cardiol (2007) 1.70

Ventricular-vascular interaction in heart failure. Heart Fail Clin (2008) 1.67

Prognostic Importance of Impaired Systolic Function in Heart Failure With Preserved Ejection Fraction and the Impact of Spironolactone. Circulation (2015) 1.64

Baseline characteristics of patients in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial. Circ Heart Fail (2012) 1.62

Diastolic stiffness as assessed by diastolic wall strain is associated with adverse remodelling and poor outcomes in heart failure with preserved ejection fraction. Eur Heart J (2012) 1.58

Heart failure with preserved ejection fraction: mechanisms, clinical features, and therapies. Circ Res (2014) 1.56

Characterization of subgroups of heart failure patients with preserved ejection fraction with possible implications for prognosis and treatment response. Eur J Heart Fail (2015) 1.54

Chronic heart failure: contemporary diagnosis and management. Mayo Clin Proc (2010) 1.51

Characterization of heart failure patients with preserved ejection fraction: a comparison between ADHERE-US registry and ADHERE-International registry. Eur J Heart Fail (2011) 1.51

Serelaxin in acute heart failure patients with preserved left ventricular ejection fraction: results from the RELAX-AHF trial. Eur Heart J (2013) 1.50

Pathological ventricular remodeling: mechanisms: part 1 of 2. Circulation (2013) 1.48

Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. Eur Heart J (2015) 1.46

The implications of a growing evidence base for drug use in elderly patients Part 2. ACE inhibitors and angiotensin receptor blockers in heart failure and high cardiovascular risk patients. Br J Clin Pharmacol (2006) 1.43

Heart failure with a normal ejection fraction. Heart (2005) 1.41

Cardiac structure and function in heart failure with preserved ejection fraction: baseline findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist trial. Circ Heart Fail (2013) 1.40

One-Year Outcomes After Transcatheter Insertion of an Interatrial Shunt Device for the Management of Heart Failure With Preserved Ejection Fraction. Circ Heart Fail (2016) 1.39

Comparison of clinical features and outcomes of patients hospitalized with heart failure and normal ejection fraction (> or =55%) versus those with mildly reduced (40% to 55%) and moderately to severely reduced (<40%) fractions. Am J Cardiol (2008) 1.32

Heart failure in patients with preserved and deteriorated left ventricular ejection fraction. Heart (2005) 1.29

Current perspectives in diastolic dysfunction and diastolic heart failure. Heart (2006) 1.26

New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes. Eur Heart J (2014) 1.25

[Guidelines for therapy of chronic heart failure]. Z Kardiol (2005) 1.24

Neutral endopeptidase inhibition and the natriuretic peptide system: an evolving strategy in cardiovascular therapeutics. Eur Heart J (2012) 1.24

Association of glucose metabolism with diastolic function along the diabetic continuum. Diabetologia (2010) 1.23

Insulin resistance and glycemic abnormalities are associated with deterioration of left ventricular diastolic function: a cross-sectional study. Cardiovasc Diabetol (2010) 1.16

A randomized double-blind trial of enalapril in older patients with heart failure and preserved ejection fraction: effects on exercise tolerance and arterial distensibility. Circ Heart Fail (2010) 1.15

Frailty and multiple comorbidities in the elderly patient with heart failure: implications for management. Heart Fail Rev (2012) 1.14

Phenotype-Specific Treatment of Heart Failure With Preserved Ejection Fraction: A Multiorgan Roadmap. Circulation (2016) 1.14

Understanding the epidemic of heart failure: past, present, and future. Curr Heart Fail Rep (2014) 1.12

Left atrial function predicts heart failure hospitalization in subjects with preserved ejection fraction and coronary heart disease: longitudinal data from the Heart and Soul Study. J Am Coll Cardiol (2012) 1.12

A systematic assessment of causes of death after heart failure onset in the community: impact of age at death, time period, and left ventricular systolic dysfunction. Circ Heart Fail (2010) 1.11

Heart Failure with Preserved Ejection Fraction: Persistent Diagnosis, Therapeutic Enigma. Curr Cardiovasc Risk Rep (2011) 1.10

Candesartan and heart failure: the allure of CHARM. Lancet (2003) 1.09

The heart failure epidemic. Int J Environ Res Public Health (2010) 1.07

Developing therapies for heart failure with preserved ejection fraction: current state and future directions. JACC Heart Fail (2014) 1.07

Angiotensin receptor blockers and outcomes in real-world older patients with heart failure and preserved ejection fraction: a propensity-matched inception cohort clinical effectiveness study. Eur J Heart Fail (2012) 1.07

Effect of oral digoxin in high-risk heart failure patients: a pre-specified subgroup analysis of the DIG trial. Eur J Heart Fail (2013) 1.06

Cardiac structure and function and prognosis in heart failure with preserved ejection fraction: findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) Trial. Circ Heart Fail (2014) 1.06

Diastolic dysfunction is associated with cardiac fibrosis in the senescence-accelerated mouse. Am J Physiol Heart Circ Physiol (2011) 1.03

Renin-angiotensin inhibition in diastolic heart failure and chronic kidney disease. Am J Med (2013) 1.03

Aging of the United States population: impact on heart failure. Curr Heart Fail Rep (2012) 1.00

Prevalence, clinical characteristics, and outcomes associated with eccentric versus concentric left ventricular hypertrophy in heart failure with preserved ejection fraction. Am J Cardiol (2013) 1.00

Integrating the myocardial matrix into heart failure recognition and management. Circ Res (2013) 1.00

Polypharmacy and excessive polypharmacy in octogenarians and older acutely hospitalized patients. Wien Klin Wochenschr (2014) 0.99

Contribution of comorbidities to functional impairment is higher in heart failure with preserved than with reduced ejection fraction. Clin Res Cardiol (2011) 0.98

Predictors of development of diabetes in patients with chronic heart failure in the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) program. Diabetes Care (2009) 0.98

New roles for renin and prorenin in heart failure and cardiorenal crosstalk. Heart Fail Rev (2012) 0.98

Contemporary strategies in the diagnosis and management of heart failure. Mayo Clin Proc (2014) 0.98

Hypokalemia and sudden cardiac death. Exp Clin Cardiol (2010) 0.98

Comparison of ventricular structure and function in Chinese patients with heart failure and ejection fractions >55% versus 40% to 55% versus <40%. Am J Cardiol (2009) 0.97

Renal dysfunction in acute and chronic heart failure: prevalence, incidence and prognosis. Heart Fail Rev (2012) 0.96

Prognostic importance of comorbidities in heart failure with preserved left ventricular ejection fraction. Heart Vessels (2010) 0.96

Analysing recurrent hospitalizations in heart failure: a review of statistical methodology, with application to CHARM-Preserved. Eur J Heart Fail (2013) 0.96

Digoxin and reduction of heart failure hospitalization in chronic systolic and diastolic heart failure. Am J Cardiol (2008) 0.96

The treatment of heart failure with preserved ejection fraction ("diastolic heart failure"). Heart Fail Rev (2006) 0.96

Targeting the renin-angiotensin-aldosterone system in heart failure. Nat Rev Cardiol (2013) 0.95

Patient selection in heart failure with preserved ejection fraction clinical trials. J Am Coll Cardiol (2015) 0.95

Rationale and design of the Karolinska-Rennes (KaRen) prospective study of dyssynchrony in heart failure with preserved ejection fraction. Eur J Heart Fail (2009) 0.95

Role of inflammation in the pathogenesis of heart failure with preserved ejection fraction and its potential as a therapeutic target. Heart Fail Rev (2014) 0.95

Risk factors for rehospitalization in heart failure with preserved ejection fraction compared with reduced ejection fraction. Heart Vessels (2014) 0.95

Exercise intolerance in heart failure with preserved ejection fraction: more than a heart problem. J Geriatr Cardiol (2015) 0.95

The novel biomarker growth differentiation factor 15 in heart failure with normal ejection fraction. Eur J Heart Fail (2010) 0.95

The influence of cardiovascular and antiinflammatory drugs on thiazide-induced hemodynamic and saluretic effects. Eur J Clin Pharmacol (2006) 0.95

Comparative assessment of angiotensin receptor blockers in different clinical settings. Vasc Health Risk Manag (2009) 0.94

Heart failure with preserved ejection fraction. Glob Cardiol Sci Pract (2012) 0.94

Effect of aldosterone antagonism on exercise tolerance, Doppler diastolic function, and quality of life in older women with diastolic heart failure. Congest Heart Fail (2009) 0.94

Sex differences in clinical characteristics and outcomes in elderly patients with heart failure and preserved ejection fraction: the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial. Circ Heart Fail (2012) 0.94

Treatment for chronic heart failure in the elderly: current practice and problems. Heart Fail Rev (2013) 0.93

Influence of previous heart failure hospitalization on cardiovascular events in patients with reduced and preserved ejection fraction. Circ Heart Fail (2014) 0.93

Heart failure with preserved ejection fraction in the elderly: scope of the problem. J Mol Cell Cardiol (2015) 0.93

Learning from recent trials and shaping the future of acute heart failure trials. Am Heart J (2013) 0.92

The underuse of digoxin in heart failure, and approaches to appropriate use. CMAJ (2007) 0.92

Angiotensin-converting enzyme inhibitors and outcomes in heart failure and preserved ejection fraction. Am J Med (2013) 0.92

Diastolic dysfunction: a link between hypertension and heart failure. Drugs Today (Barc) (2008) 0.91

Comparative effects of angiotensin-converting enzyme inhibition and angiotensin-receptor blockade on inflammation during hemodialysis. J Am Soc Nephrol (2011) 0.90

Chronic heart failure in older adults. Med Clin North Am (2011) 0.90

The past, present and future of renin-angiotensin aldosterone system inhibition. Int J Cardiol (2012) 0.90

AT1-receptor-deficiency induced atheroprotection in diabetic mice is partially mediated via PPARγ. Cardiovasc Diabetol (2013) 0.89

Office management of patients with diastolic heart failure. CMAJ (2009) 0.88

Exercise training improves heart rate variability in older patients with heart failure: a randomized, controlled, single-blinded trial. Congest Heart Fail (2012) 0.87

Articles by these authors

Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med (2011) 23.50

Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med (2004) 19.42

A common variant on chromosome 9p21 affects the risk of myocardial infarction. Science (2007) 18.96

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet (2003) 17.34

Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med (2010) 14.43

A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med (2009) 14.13

Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet (2005) 12.92

2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J (2013) 12.73

Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med (2005) 12.46

Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med (2009) 12.44

ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J (2008) 12.32

2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2013) 11.88

Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med (2014) 11.77

Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med (2013) 11.14

Guidelines on the management of valvular heart disease (version 2012). Eur Heart J (2012) 10.70

Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med (2003) 10.57

2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation (2013) 10.07

Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet (2003) 9.98

Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet (2003) 9.80

Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J (2007) 9.80

Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA (2004) 9.74

Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med (2004) 9.67

C-reactive protein levels and outcomes after statin therapy. N Engl J Med (2005) 9.47

Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med (2012) 9.46

Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med (2006) 9.40

Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med (2004) 9.13

Dronedarone in high-risk permanent atrial fibrillation. N Engl J Med (2011) 8.93

Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med (2015) 8.69

Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet (2009) 8.54

Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA (2002) 8.28

AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation (2006) 8.01

2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2012) 7.94

Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med (2012) 7.93

Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis. N Engl J Med (2007) 7.86

Rosuvastatin in older patients with systolic heart failure. N Engl J Med (2007) 7.55

Spironolactone for heart failure with preserved ejection fraction. N Engl J Med (2014) 7.48

A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry. JAMA (2004) 7.32

2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation (2012) 6.94

Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. N Engl J Med (2005) 6.86

Sequence variants affecting eosinophil numbers associate with asthma and myocardial infarction. Nat Genet (2009) 6.83

ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail (2008) 6.80

The same sequence variant on 9p21 associates with myocardial infarction, abdominal aortic aneurysm and intracranial aneurysm. Nat Genet (2008) 6.72

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet (2003) 6.55

Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA (2007) 6.25

Decline in rates of death and heart failure in acute coronary syndromes, 1999-2006. JAMA (2007) 6.06

Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med (2010) 6.05

A sensitive cardiac troponin T assay in stable coronary artery disease. N Engl J Med (2009) 5.81

Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA (2006) 5.74

A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. Am J Med (2002) 5.55

Guidelines on the management of valvular heart disease (version 2012): the Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur J Cardiothorac Surg (2012) 5.49

Erythropoietic response and outcomes in kidney disease and type 2 diabetes. N Engl J Med (2010) 5.48

Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. Lancet (2010) 5.30

Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med (2006) 5.24

ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J (2013) 5.23

Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. JAMA (2004) 5.11

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet (2003) 4.99

The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens (2003) 4.91

Use of ramipril in preventing stroke: double blind randomised trial. BMJ (2002) 4.91

Early versus delayed invasive intervention in acute coronary syndromes. N Engl J Med (2009) 4.83

Red cell distribution width as a novel prognostic marker in heart failure: data from the CHARM Program and the Duke Databank. J Am Coll Cardiol (2007) 4.74

Treatment of anemia with darbepoetin alfa in systolic heart failure. N Engl J Med (2013) 4.67

Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. N Engl J Med (2015) 4.56

ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries: the Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC). Eur Heart J (2011) 4.47

Azithromycin for the secondary prevention of coronary heart disease events: the WIZARD study: a randomized controlled trial. JAMA (2003) 4.44

Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA (2007) 4.30